Statement by FTC Chairman Jon Leibowitz Regarding Cephalon Decision

Statement by FTC Chairman Jon Leibowitz Regarding Today's District Court Decision Denying a Motion to Dismiss the Commission's Pay-For-Delay Case Against Cephalon Inc.
Today's decision seems to reflect a growing understanding-first in Congress now in the courts-that brand name drug companies must not be allowed to make pay-offs to their generic competitors to keep low-cost generic drugs off the market. These deals are costing American consumers $3.5 billion a year in higher drug costs.

MEDIA CONTACT:
Office of Public Affairs
202-326-2180

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.